D&D Pharmatech Valuation Multiples

D&D Pharmatech Overview

About D&D Pharmatech

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

Founded

2014

HQ

Employees

N/A

Website

ddpharmatech.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $11M

EBITDA: ($20M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

D&D Pharmatech Financials

D&D Pharmatech reported last 12-month revenue of $11M and negative EBITDA of ($20M).

In the same LTM period, D&D Pharmatech generated $11M in gross profit, ($20M) in EBITDA losses, and had net loss of ($22M).

D&D Pharmatech P&L

In the most recent fiscal year, D&D Pharmatech reported revenue of $8M and EBITDA of ($16M).

D&D Pharmatech expects next 12-month revenue of XXX and NTM EBITDA of XXX

D&D Pharmatech Stock Performance

D&D Pharmatech has current market cap of $2B, and enterprise value of $2B.

D&D Pharmatech's stock price is $57.38.

D&D Pharmatech Valuation Multiples

D&D Pharmatech trades at 226.7x EV/Revenue multiple, and (126.6x) EV/EBITDA.

D&D Pharmatech Financial Valuation Multiples

As of March 7, 2026, D&D Pharmatech has market cap of $2B and EV of $2B.

Equity research analysts estimate D&D Pharmatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

D&D Pharmatech has a P/E ratio of (114.0x).

D&D Pharmatech Margins & Growth Rates

D&D Pharmatech's revenue in the last 12 month grew by 38%.

D&D Pharmatech's rule of 40 is (141%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

D&D Pharmatech's rule of X is (83%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

D&D Pharmatech Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

D&D Pharmatech M&A Activity

D&D Pharmatech acquired XXX companies to date.

Last acquisition by D&D Pharmatech was on XXXXXXXX, XXXXX. D&D Pharmatech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

D&D Pharmatech Investment Activity

D&D Pharmatech invested in XXX companies to date.

D&D Pharmatech made its latest investment on XXXXXXXX, XXXXX. D&D Pharmatech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).